PRESS RELEASE published on 05/26/2026 at 19:00, 2 months 9 days ago Inside Information / Other news releases MaaT Pharma provides a business update and reports financial results for the first quarter of 2026, highlighting regulatory activities and cash position. Lyon, France Financial Results Business Update Cash Position MaaT Pharma Regulatory Activities
BRIEF published on 05/20/2026 at 20:50, 2 months 15 days ago MAAT Pharma Faces Setback in Authorization for MaaT013 Biotech MaaT Pharma EMA MaaT013 AGvHD
PRESS RELEASE published on 05/20/2026 at 20:45, 2 months 15 days ago Inside Information / Other news releases MaaT Pharma receives a 'negative trend' opinion from CHMP for their Marketing Authorization Application of MaaT013 (Xervyteg) in acute Graft-versus-Host Disease treatment. Company plans re-examination procedure MaaT Pharma CHMP Marketing Authorization Negative Trend Re-examination
BRIEF published on 04/21/2026 at 15:14, 3 months 13 days ago MaaT Pharma SACA Maintains Buy Rating with Stable Financial Outlook Financial Performance BUY Rating Pipeline Development MaaT Pharma Investment Case
PRESS RELEASE published on 04/21/2026 at 15:09, 3 months 13 days ago Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research reaffirms Buy rating for MaaT Pharma SACA with a target price of €17 following FY25 results and pipeline update. No changes to core investment case First Berlin Equity Research BUY Rating MaaT Pharma SACA FY25 Results €17 Target Price
BRIEF published on 04/01/2026 at 07:35, 4 months 3 days ago MaaT Pharma publishes data on aGvH in "Bone Marrow Transplantation" MaaT Pharma EMA AGvH Xervyteg® CHRONOS
BRIEF published on 04/01/2026 at 07:35, 4 months 3 days ago MaaT Pharma Presents CHRONOS Study Results on Third-Line Acute GvHD MaaT Pharma Regulatory Review CHRONOS Study Acute GvHD Third-line Therapy
PRESS RELEASE published on 04/01/2026 at 07:30, 4 months 3 days ago Inside Information / Other news releases MaaT Pharma announces publication of retrospective data from CHRONOS study in Bone Marrow Transplantation Journal, presenting real-world outcomes of third-line systemic treatments for GI-aGvHD patients MaaT Pharma GI-aGvHD CHRONOS Study Retrospective Data Bone Marrow Transplantation
BRIEF published on 03/31/2026 at 07:35, 4 months 4 days ago MaaT Pharma: 2025 Revenue and Clinical Progress Revenue Funding Clinical Development MaaT Pharma Microbiothérapies
BRIEF published on 01/20/2026 at 18:35, 6 months 15 days ago MaaT Pharma Launches Phase 2 Trial for NSCLC Patients NSCLC MaaT Pharma Gut Microbiome IMMUNOLIFE Phase 2 Antibiotic-induced Dysbiosis
Published on 08/04/2026 at 16:25, 5 hours 26 minutes ago ACCESS Newswire to Host Second Quarter Earnings Conference Call on August 11, 2026
Published on 08/04/2026 at 15:00, 6 hours 51 minutes ago Infield Minerals Expands Land Position at the Kings Canyon Gold Project in Utah
Published on 08/04/2026 at 15:00, 6 hours 51 minutes ago Secure Blockchain's Agentic Solutions Signs First Enterprise AI Customer
Published on 08/04/2026 at 14:30, 7 hours 21 minutes ago Agassi Sports Entertainment Launches Global "Let's Play" Pickleball and Padel Platform Initiative
Published on 08/04/2026 at 14:30, 7 hours 21 minutes ago Innodata Releases the First Stage of Its AI Cyber Training Suite to Enable AI Coding Agents to Write - and Repair - Secure Code
Published on 08/04/2026 at 20:05, 1 hour 46 minutes ago Hard Rock Cafe and Coca-Cola® Launch Hard Rock Rising Music Competition for Emerging Artists
Published on 08/04/2026 at 19:39, 2 hours 12 minutes ago EQS-Adhoc: Basler AG financial results for the first 6 months of 2026: Strong business performance in the first half of the year; company raises its 2026 forecast once again
Published on 08/04/2026 at 18:25, 3 hours 26 minutes ago Amendment to the Prospectus of the Company and the Key Information Documents of the SubFunds
Published on 08/04/2026 at 18:32, 3 hours 19 minutes ago Total number of voting rights and shares making up the share capital at July 31, 2026
Published on 08/04/2026 at 17:45, 4 hours 6 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 08/04/2026 at 16:00, 5 hours 51 minutes ago MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
Published on 08/04/2026 at 08:15, 13 hours 36 minutes ago Covivio - Conditions of availability of the 2026 Half-year report
